VAXXITEK® HVT+IBD+H5 is a groundbreaking trivalent vaccine developed to protect poultry from three major diseases: Marek’s Disease, Infectious Bursal Disease (IBD), and H5 Avian Influenza, all with a single shot.
H5 Avian Influenza is a highly contagious and notifiable zoonotic disease that has a significant global impact on the poultry industry, affecting farmers and international trade.
Administering the vaccine at the hatchery provides early protection for chicks, reducing the risk of an immunity gap between the decline of maternal antibodies and the development of active immunity.
With the launch of VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim expands its trusted VAXXITEK® portfolio by introducing a vaccine that provides comprehensive protection against three severe poultry diseases. The vaccine is set to launch for the first time globally in Egypt in February 2025.
Targeted Diseases: Major Challenges for the Poultry Industry
Marek’s Disease: A viral disease in chickens that can cause tumors, paralysis, and often death, leading to significant financial losses for poultry farmers.
Infectious Bursal Disease (IBD): Also known as Gumboro disease, this viral infection results in symptoms such as diarrhea and dehydration, negatively affecting productivity.
H5 Avian Influenza: One of the most widespread and dangerous strains of bird flu, present year-round in several countries. Vaccination is essential to control the virus’s spread, particularly given its constant evolution and the emergence of new variants.
Supporting Poultry Producers with Technology and Ease of Use
Taoufik Rawi, Head of Poultry Franchise at Boehringer Ingelheim, stated:
“The launch of VAXXITEK® HVT+IBD+H5 is a significant step forward in avian influenza prevention, offering both comprehensive coverage and convenience.
Our goal is to help customers keep their flocks healthy and thriving. This innovative three-in-one vaccine provides broad protection against the most prevalent H5 avian influenza clades and two other major poultry diseases—all in a single shot.”
This vaccine utilizes COBRA technology (Computationally Optimized Broadly Reactive Antigen) to create a unique antigen sequence that offers protection against the most infectious and prevalent H5 clades.
Expert Opinions on the Vaccine Launch
Dr. David Swayne, Former Laboratory Director at the USDA and Adjunct Professor at the University of Georgia, USA, commented:
“The continuous evolution of H5 Avian Influenza presents a global challenge for poultry health. Innovations in disease management strategies, particularly vaccination, play a vital role in protecting poultry flocks from the damaging effects of this virus.”
Commitment to Sustainable Poultry Farming in the Region
Waleed El Mashak, Head of Animal Health for India, Middle East, Turkey, and Africa (IMETA) at Boehringer Ingelheim, remarked:
“The introduction of VAXXITEK® HVT+IBD+H5 in Egypt is a significant advancement for poultry farmers across the IMETA region, which has been heavily affected by avian influenza. This launch demonstrates our commitment to supporting sustainable poultry farming.”
Magdy Hassan, President of the Egyptian Veterinary Syndicate, added:
“The introduction of VAXXITEK® HVT+IBD+H5 in Egypt marks a milestone for poultry farmers, offering an effective solution to strengthen flock immunity and protect against major diseases, including H5 avian influenza. This development supports the growth and sustainability of the poultry industry.”
Mahmoud El Mahdy, Country Head of Animal Health for North, East, and West Africa at Boehringer Ingelheim, stated:
“As leaders in animal health, we are dedicated to supporting our customers in raising poultry in a healthy, sustainable, and economically viable manner. Launching VAXXITEK® HVT+IBD+H5 in Egypt is a major step forward, offering an advanced, scientifically proven solution for a country where poultry farming is vital for food security and economic growth.”
El Mahdy further added:
“This vaccine introduction represents a game-changing approach to disease control, supporting market stability and securing international trade opportunities. Boehringer Ingelheim remains committed to providing cutting-edge innovations that strengthen Egypt’s poultry industry and promote sustainable food production.”
About Boehringer Ingelheim
Boehringer Ingelheim is a leading biopharmaceutical company specializing in both human and animal health. As one of the top investors in research and development, the company focuses on developing innovative therapies to address unmet medical needs.
Founded in 1885, Boehringer Ingelheim remains an independent entity with a long-term commitment to embedding sustainability across the entire value chain. The company employs over 53,500 people across more than 130 markets, striving to build a healthier, more sustainable, and equitable future.
Learn more at: www.boehringer-ingelheim.com/animal-health
